Integra LifeSciences Announces Launch of Integra(R) Flowable Wound Matrix in Europe for Diabetic Foot and Leg Ulcers

Integra LifeSciences Announces Launch of Integra(R) Flowable Wound Matrix in
Europe for Diabetic Foot and Leg Ulcers

Device Awarded Most Innovative New Product by French Society of Reconstructive
& Esthetic Plastic Surgery

PLAINSBORO, N.J., Jan. 18, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences
Holdings Corporation (Nasdaq:IART) today announced that it has received
European CE Mark Certification for its Integra^® Flowable Wound Matrix, an
advanced device approved in the European Union for filling deep soft tissue or
tunneling wounds, including diabetic foot and leg ulcers.

The Société Française de Chirurgie Plastique Reconstructrice et Esthétique
(SOF.CPRE) (French Society of Reconstructive and Esthetic Plastic Surgery),
one of Europe's pre-eminent medical associations, has also awarded Integra's
Flowable Wound Matrix 1^st place in its innovation contest. Each year, over
1,000 surgeons attend the annual meeting and are asked to vote on the most
innovative new product, based on its performance.This year, the majority of
the voters selected Integra's Flowable Wound Matrix.

"We are extremely honored that Integra's Flowable Wound Matrix has been
recognized by surgeons as one of the most innovative new products available
for the management of chronic wounds," said Debbie Leonetti, Integra's
Corporate Vice President, President - International."Tens of thousands of
patients in Europe suffer from chronic foot and leg ulcers that progress to
deep or tunneling wounds, and they face serious risk of amputation.Integra's
Flowable Wound Matrix now offers surgeons, and patients, a new option for
managing these hard-to-access wounds."

Integra^® Flowable Wound Matrix is the flowable version of Integra's wound
matrix and uses the company's proven collagen technology, whose effectiveness
has been widely demonstrated over the past 20 years in a variety of
indications, including life-threatening burns and scar revisions.The
product's release in Europe is backed by five years of use in the United
States and Latin America, where it is already used to meet the specific
clinical requirements for managing wounds, including partial and
full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular
ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds and
draining wounds. 

"The product's reputation has spread well beyond American borders, and many
European wound specialists are waiting for it," said Marie-Ange Passemard,
EMEAMarketing and Sales Director, Integra Skin and Wound. "Thanks to its
release on the European market, we will be able to meet demand from centers
specialized in treating chronic wounds, which are faced with a steep increase
in the number of diabetes-related pathologies. This is good news for patients,
who will have an alternative to the usual treatment for their wounds."

The incidence of diabetes continues to accelerate, affecting approximately 55
million people in the European Union, of which an estimated 3 million will
develop a foot ulcer. Between 15% and 20% of these ulcers eventually result
in an amputation. However, many of these amputations could be prevented with
proper intervention.

Integra^® Flowable Wound Matrix is sold by Integra's European Skin and Wound
sales organization.

Integra LifeSciences, a world leader in medical devices, is dedicated to
limiting uncertainty for surgeons, so they can concentrate on providing the
best patient care. Integra offers innovative solutions in orthopedics,
neurosurgery, spine, reconstructive and general surgery. For more information,

The Integra LifeSciences Holdings Corp. logo is available at

This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, statements concerning the products
and services provided by Integra. Such forward looking statements involve
risks and uncertainties that could cause actual results to differ materially
from predicted or expected results. Among other things, the willingness of
surgical professionals to use Integra products may affect the prospects for
their use in surgical procedures. In addition, the economic, competitive,
governmental, technological and other factors, identified under the heading
"Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for
the year ended December 31, 2011 and information contained in subsequent
filings with the Securities and Exchange Commission could affect actual

CONTACT: United States:
         Integra LifeSciences Holdings Corporation
         Gianna Sabella
         Director, Corporate Communications
         (609) 936-2389
         Integra LifeSciences Holdings Corporation
         Marie-Anne Girel
         Manager, Communications
         Europe, Middle-East, Africa

Company Logo
Press spacebar to pause and continue. Press esc to stop.